Carol Gail Ashe - 31 Aug 2026 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Director
Issuer ticker: ELTX
Reported as of: 31 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2026, 16:04:55 UTC
Prior SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Carol Ashe

Key filing fact

Carol Gail Ashe filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 02 Sep 2026.

Key facts

This page summarizes Carol Gail Ashe's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Sep 2026, 16:04.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001761748 Primary reporting owner

Ashe Carol Gail

Relationship: Director
Address: C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON
Signature: /s/ Carol Ashe
Signature date: 02 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +21,750
Change %
Price: $0.000000^*
Shares after: 21,750
Date: 31 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,750
Exercise price: $2.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.